Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04226274 | A Study of the Safety of REN001 in Patients With McArdle Disease | PHASE1 | COMPLETED | 19 | — | — | Dec 10, 2019 | Oct 11, 2021 | Jan 12, 2022 | 2 | Spain, United Kingdom |
Number of participants with Adverse Events (AEs) as a measure of safety and tolerability
| Arm | Type | Description |
|---|---|---|
| REN001 | EXPERIMENTAL | Oral |
| Name | Type | Description |
|---|---|---|
| REN001 | DRUG | Once daily for 12 weeks |
Inclusion Criteria: * Subjects must give written, signed and dated informed consent * Confirmed diagnosis of McArdle Disease * Subjects must be able to remain on stable medication through the study and specifically must not commence or have changes to agents that affect metabolism such as medicatio...